71 filings
8-K/A
CNSP
Cns Pharmaceuticals Inc
20 Jun 24
Financial Statements and Exhibits
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
14 Jun 24
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
5:25pm
8-K
CNSP
Cns Pharmaceuticals Inc
5 Jun 24
CNS Pharmaceuticals Announces Reverse Stock Split
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
16 May 24
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
10:56am
8-K
CNSP
Cns Pharmaceuticals Inc
7 May 24
Other Events
5:00pm
8-K
37cnp mk7b5njts
3 May 24
Departure of Directors or Certain Officers
4:26pm
8-K
y0tmdpfmrf6
12 Apr 24
Regulation FD Disclosure
6:37pm
8-K
ngmssh
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
8-K
jlm6jqigee3xe6qaec
27 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
njkmkfjl 3xmr6k5
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
d4ytexmn0bx1325icb6
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
d8lqt r1s
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
8-K
xjv9vorm
21 Dec 23
Regulation FD Disclosure
9:15am
8-K
2fu2c1 xlgihd
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
enwtn1 w7qoe2yuoru
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
8anfskh1ui4ffx
18 Oct 23
Regulation FD Disclosure
9:00am
8-K
3m8g9xh
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
gtk2s
18 Sep 23
Submission of Matters to a Vote of Security Holders
7:51pm
8-K
4hzy2xax5sz0 pjkw
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
fnceanhbv9r
15 Aug 23
Amendments to Articles of Incorporation or Bylaws
8:30am